Storm Therapeutics

Storm’s First-in-Class clinical candidate against an RNA Methyltransferase for use in Cancer was identifed with support from Evotec’s Drug Discovery Engine. Storm will progress the compound towards the clinic using indigo, Evotec’s integrated Ivestigational New Drug […]

Cambridge, UK.  22 October 2020.  Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced  that STC-15, its first-in-class drug candidate targeting […]

Dublin, Ireland.  9 September 2020.  FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA […]

Cambridge, UK.  18 September 2019.   STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced today that Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, will present first […]

Cambridge, UK.  20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that it has raised an additional £14 million bringing its total Series A financing to […]

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top